wild type wt cell lines hct116 (ATCC)
Structured Review

Wild Type Wt Cell Lines Hct116, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 17738 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hct116+wild+type+wt+cell+line/bio_rxiv__2025__08__22__671824-34-0-15?v=ATCC
Average 99 stars, based on 17738 article reviews
Images
1) Product Images from "MCL1 may not mediate chemoresistance"
Article Title: MCL1 may not mediate chemoresistance
Journal: bioRxiv
doi: 10.1101/2025.08.22.671824
Figure Legend Snippet: MCL1 KO/KD cell line and CST #5453 anti-MCL1 antibody validation by western blot in A ). HCT116, B ). HeLa, C ). HEK293 and D ). MEFs and by IF microscopy in E ). HEK293 cells. SCR = scramble siRNA (negative control). IF images were taken at 40x magnification. Data are representative of three independent experiments.
Techniques Used: Biomarker Discovery, Western Blot, Microscopy, Negative Control
Figure Legend Snippet: Summary of results from chemosensitivity studies on WT vs. MCL1 KO/KD cells in both 96-well and 384-well plate formats. One-way ANOVA with multiple comparisons of pGI50 values for each WT and MCL1 KO/KD pair are shown for A) . HCT116, B) . HeLa and C) . MEFs as a result of 48-h chemotherapy treatment in 96-well plates. Multiplicity adjusted P values were obtained for each comparison to determine statistical significance; P > 0.05 (ns), P ≤ 0.05 (*), P ≤ 0.01 (**); ns = not significant. Three pGI50 values were extracted for each WT and MCL1 KO/KD cell line treated with the five chemotherapies since cell viability assays were performed in biological triplicate. SCR = scramble siRNA (negative control). Heatmaps depicting the comparison of mean AUC values for WT and MCL1 KO D-G) HCT116 and H-K) . HeLa cell lines treated with dose titrations of PACL, VINC, VINO, DOX or ETOPO in 384-well plates. Areas were obtained under each percent confluence vs. time growth curve shown in Figure S2A-B . AUCs were averaged from treatments performed in technical triplicate.
Techniques Used: Comparison, Negative Control
Figure Legend Snippet: Restoration of MCL1 WT and overexpression of MCL1 NLS in MCL1 KO cell lines to study their effects on chemoresistance. A) . Validation of MCL1 WT and MCL1 NLS localization in MCL1 KO HCT116 and HeLa cells by subcellular fractionation. CYTO = cytosolic fraction; NUC = nuclear fraction. B-C) . Normalization and quantitation of nuclear FLAG expression of MCL1 WT and MCL1 NLS in MCL1 KO HCT116 and HeLa cells, respectively. One-way ANOVA with multiple comparisons of pGI50 values for MCL1 KO vs. KO cell lines reconstituted with MCL1 WT or MCL1 NLS in D) . HCT116 and E) . HeLa for each chemotherapy treatment. Multiplicity adjusted P values were obtained for each comparison to determine statistical significance; P > 0.05 (ns), P ≤ 0.05 (*), P ≤ 0.01 (**); ns = not significant. Three pGI50 values were extracted for each KO and KO cell lines reconstituted with MCL1 WT or MCL1 NLS treated with the five chemotherapies since cell viability assays were performed in biological triplicate.
Techniques Used: Over Expression, Biomarker Discovery, Fractionation, Quantitation Assay, Expressing, Comparison
Figure Legend Snippet: MCL1 nuclear translocation assays in HCT116 and HeLa cells. A) . Subcellular fractionation assessment of MCL1 nuclear translocation in response to overnight (20 hr) doxorubicin (DOX), etoposide (ETOPO), paclitaxel (PACL) and oxaliplatin (OXAL) treatments in HeLa cells. CYTO = cytosolic fraction; NUC = nuclear fraction. B) . Subcellular fractionation assessment of MCL1 nuclear translocation in response to 3 hr etoposide treatments. NUC S = soluble nuclear proteins; NUC CHR = chromatin-bound nuclear proteins. C) . IF evaluation of MCL1 nuclear translocation in response to 20 hr chemotherapy treatments in HCT116 and HeLa cells. IF images were taken at 40x magnification. Data are representative of two independent experiments.
Techniques Used: Translocation Assay, Fractionation
Figure Legend Snippet: Proximity biotinylation experimental design and results. A) . Schematic of proximity biotinylation approach with arbitrary MCL1-TurboID fusion construct (figure modified from BioRender ). B). MCL1 TurboID plasmid fusion construct design (75 kDa, 700 aa). C) . Validation of GFP TurboID and MCL1 TurboID nuclear localization in HCT116 and HeLa cells by subcellular fractionation. CYTO = cytosolic fraction; NUC = nuclear fraction. D) . Venn diagram comparing number of newly defined MCL1 interactors between HCT116 and HeLa cells with SAINT SP > 0.8. Box shows the 18 shared MCL1 interactors (both nuclear and cytosolic) between both cell lines. Proximity biotinylation experiments were performed in technical triplicate.
Techniques Used: Construct, Modification, Plasmid Preparation, Biomarker Discovery, Fractionation

